Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Date publication

mai 2018

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent , Pr BOUCHE Olivier , Pr LEPAGE Côme

Tous les auteurs :
Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29807237

Résumé

Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI.

Mots clés

Bevacizumab, Colorectal cancer, Overweight, Pooled analysis, Prognostic factor

Référence

Eur. J. Cancer. 2018 May 25;98:1-9